简体中文
繁體中文
English
Pусский
日本語
ภาษาไทย
Tiếng Việt
Bahasa Indonesia
Español
हिन्दी
Filippiiniläinen
Français
Deutsch
Português
Türkçe
한국어
العربية
Novartis earnings edge higher on Cosentyx, Entresto
Abstract：(Reuters) – Core operating income at Novartis edged 3% higher in the first quarter as sales growth from new drugs was partly offset by unfavourable currency effects.
Reuters – Core operating income at Novartis edged 3 higher in the first quarter as sales growth from new drugs was partly offset by unfavourable currency effects.
Quarterly core operating income rose to 4.08 billion, up from 3.96 billion a year earlier, the Swiss drugmaker said on Tuesday
Quarterly revenues from arthritis and psoriasis drug Cosentyx gained 12 in constant currencies to 1.16 billion, slightly belowabove analysts average forecast of 1.19 billion, based on Refinitiv data.p
Revenues from heart failure treatment Entresto jumped 42 to 1.1 billion, surpassing the market consensus of 1 billion.
Disclaimer:
The views in this article only represent the author's personal views, and do not constitute investment advice on this platform. This platform does not guarantee the accuracy, completeness and timeliness of the information in the article, and will not be liable for any loss caused by the use of or reliance on the information in the article.
WikiFX Broker
Latest News
BI Apprehends Japanese Scam Leader in Manila
WikiFXBitcoin in 2025: The Opportunities and Challenges Ahead
WikiFXJoin the Event & Level Up Your Forex Journey
WikiFXIs There Still Opportunity as Gold Reaches 4-Week High?
WikiFXBitcoin miner\s claim to recover £600m in Newport tip thrown out
WikiFXGood News Malaysia: Ready for 5% GDP Growth in 2025!
WikiFXHow to Automate Forex and Crypto Trading for Better Profits
WikiFXFXCL Lucky Winter Festival Begins
WikiFXWarning Against MarketsVox
WikiFXIs the stronger dollar a threat to oil prices?
WikiFXCurrency Calculator
